India, Aug. 25 -- Vitruvias Therapeutics Inc., based in Auburn Alabama, on August 24, 2026, announced a nationwide recall of one lot of its Thyroid Tablets, USP 30 mg, due to the potential for the product to be superpotent, as noted in an FDA safety posting.
The recall involves Lot No. 504950, distributed across the United States between January and September 2025. Testing confirmed that the tablets may contain higher-than-intended levels of active thyroid hormones.
Superpotent thyroid medication can lead to hyperthyroidism, a condition marked by symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, and irregular heart rhythms.
The FDA noted that elderly patients, pregnant...